InicioIMM • ASX
add
Immutep Ltd
Cierre anterior
0,31 $
Intervalo diario
0,30 $ - 0,32 $
Intervalo anual
0,23 $ - 0,46 $
Cap. bursátil
479,94 M AUD
Volumen medio
3,92 M
Relación precio-beneficio
-
Rentabilidad por dividendo
-
Bolsa de valores principal
ASX
En las noticias
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
| (AUD) | jun 2024info | Cambio interanual |
|---|---|---|
Ingresos | 865,57 mil | -4,89 % |
Gastos operativos | 2,03 M | -10,92 % |
Ingresos netos | -10,74 M | -11,49 % |
Margen de beneficio neto | -1,24 mil | -17,23 % |
Beneficios por acción | — | — |
EBITDA | -11,21 M | -17,52 % |
Tipo impositivo efectivo | — | — |
Balance general
Activos totales
Responsabilidades totales
| (AUD) | jun 2024info | Cambio interanual |
|---|---|---|
Efectivo y a corto plazo | 181,88 M | 47,37 % |
Activos totales | 201,58 M | 36,71 % |
Responsabilidades totales | 12,06 M | 9,82 % |
Patrimonio total | 189,52 M | — |
Acciones en circulación | 1452,61 M | — |
Precio-valor contable | 2,38 | — |
Rentabilidad económica | -14,53 % | — |
Retorno sobre capital | -15,32 % | — |
Flujo de caja
Variación neta del flujo de caja
| (AUD) | jun 2024info | Cambio interanual |
|---|---|---|
Ingresos netos | -10,74 M | -11,49 % |
Efectivo de operaciones | -8,19 M | 30,16 % |
Efectivo de inversión | -10,30 M | -87.445,92 % |
Efectivo de financiación | 47,81 M | 25,58 % |
Variación neta del flujo de caja | 29,03 M | 5,47 % |
Flujo de caja libre | -6,10 M | -44,31 % |
Información sobre la empresa
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis Wikipedia
Director ejecutivo
Fundación
2001
Sitio web
Empleados
19
